Prestige Biologics Adjusts Conversion Price of 3rd Series CB, Resulting in Minor Dilution
Prestige Biologics lowered the conversion price of its 3rd series unlisted convertible bond from 2,524 KRW to 2,474 KRW due to a decline in the market price.
As a result, the number of convertible shares increased by 364,328 shares from 18,026,941 to 18,391,269, representing a dilution of approximately 0.47%.
This adjustment was made automatically according to the bond terms and did not require a separate board resolution; no new fundraising or management changes occurred.
While the lower conversion price increases potential share count, the dilution is minimal and short-term impact on shareholder value is limited.
[AI Summary]Prestige Biologics adjusted its CB conversion price due to market decline, causing minor dilution. This routine adjustment involves no new capital or governance changes, posing low risk. The impact on shareholder value is limited, and stock performance depends on operational results.